Tirzepatide + Placebo
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Overweight
Conditions
Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
Trial Timeline
Feb 8, 2023 → Oct 1, 2026
NCT ID
NCT05536804About Tirzepatide + Placebo
Tirzepatide + Placebo is a phase 2 stage product being developed by Eli Lilly for Overweight. The current trial status is active. This product is registered under clinical trial identifier NCT05536804. Target conditions include Overweight, Obesity, Chronic Kidney Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06962280 | Phase 3 | Active |
| NCT06914895 | Phase 3 | Active |
| NCT06191848 | Approved | Recruiting |
| NCT06439277 | Phase 3 | Recruiting |
| NCT05708859 | Approved | Recruiting |
| NCT06075667 | Phase 3 | Active |
| NCT06037252 | Phase 2 | Active |
| NCT06047548 | Phase 3 | Active |
| NCT05963022 | Phase 3 | Completed |
| NCT05536804 | Phase 2 | Active |
| NCT05696847 | Phase 1 | Completed |
| NCT05691712 | Phase 3 | Completed |
| NCT05556512 | Phase 3 | Active |
| NCT05412004 | Phase 3 | Completed |
| NCT05024032 | Phase 3 | Completed |
| NCT04235959 | Phase 1 | Completed |
| NCT04081337 | Phase 1 | Completed |
| NCT04050553 | Phase 1 | Completed |
| NCT04184622 | Phase 3 | Completed |
| NCT04166773 | Phase 2 | Completed |
Competing Products
20 competing products in Overweight